Drug Discovery and Development
Byondis is engineering precision-built ADCs to overcome cancer’s toughest challenges. Our proprietary pipeline combines novel payload platforms, advanced masking technology, and optimized linker strategies to tackle the cancers that current therapies cannot reach.
We create molecules that matter in the lives of patients – not just symptom-managing, but disease-modifying innovations. We call this “making hope real.”
Our pipeline reflects over 20 years of ADC expertise across research, lead identification, preclinical and clinical development, and manufacturing, all focused on enabling ADCs to fulfill their therapeutic potential.
Swipe
Pipeline: modular platforms for targeted solutions
We are rapidly advancing our lead proprietary program, BYON14156, to the clinic, which has demonstrated efficacy in various tumor models and a benign safety profile in NHPs.
Our Science
We employ the latest insights in tumor biology and immunology in our search for new molecular targets and development of new mechanisms for antibody-drug conjugates (ADCs) and small molecule programs.
Platforms
Our antibody drug conjugate (ADC) technology platforms are generating potential first and best in class assets, including novel proprietary payloads, linker and drug conjugation and improved targeting. This includes clinically validated MOAs, dual payloads, tumor and site-specific release, optimized antibody scaffolds and increased tumor selectivity. These platforms are enabling us to forge a new pathway in ADC development and oncology treatment.
